Trial Profile
A Retrospective study to evaluate Crizotinib versus pemetrexed and other chemotherapy regimens as first line therapy in patients with ALK+ advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Antineoplastics; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Aug 2018 New trial record